Detailed Coverage

Bliss GVS Pharma Open Offer Timeline Revised

Bliss GVS Pharma Ltd shareholders will note a revised timeline for the open offer by Anupam Rasayan India Limited and Mates Visa Consultancy Private Limited. The offer aims to acquire up to 27,726,848 equity shares, representing 26.00% of the expanded voting capital, at an offer price of ₹299.00 per share.

Reader Takeaway: Revised tendering period offers clarity; investors must act by August 10.

What just happened

The acquirers, Anupam Rasayan India Limited and Mates Visa Consultancy Private Limited, have officially announced a revised schedule for their open offer to acquire shares in Bliss GVS Pharma Limited. This update clarifies the critical dates for shareholders wishing to participate in the tender offer.

Why this matters

This open offer signifies a substantial change in the shareholding pattern of Bliss GVS Pharma. The revised timeline is crucial for existing shareholders to make informed decisions about tendering their shares within the specified period. The offer price of ₹299.00 per share provides a benchmark for the valuation being placed on the company by the acquirers.

The backstory

Anupam Rasayan India Limited, along with Mates Visa Consultancy Private Limited, is making an open offer for Bliss GVS Pharma. This is a regulatory process allowing existing shareholders to sell their shares to the acquirers at a pre-determined price.

What changes now

The key change is the update to the tendering period. The commencement of the tendering period has been moved to July 29, 2026, and it will now close on August 10, 2026. Other associated dates, including the payment and refund date, have also been adjusted accordingly.

Risks to watch

Shareholders must ensure they adhere to the revised tendering dates. Missing the deadline means forfeiting the opportunity to sell shares at the offer price. The success of the offer also depends on the number of shares tendered by eligible shareholders.

Peer comparison

While specific peer open offers are not detailed here, such transactions in the pharmaceutical sector often involve significant strategic considerations for both acquirers and target companies. The offer price reflects the current market valuation and future prospects perceived by the bidding entities.

Context metrics (time-bound)

• Offer Price: ₹299.00 per share
• Offer Size (Shares): 27,726,848 shares
• Offer Size (% of Voting Capital): 26.00%
• Revised Tendering Period: July 29, 2026, to August 10, 2026
• Revised Payment/Refund Date: August 24, 2026

What to track next

Investors should monitor the final acceptance ratio of the open offer and any subsequent corporate actions or integration plans announced by the acquirers post the completion of the offer.